SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Synlogic Inc (SYBX) is rated D (1.4/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Momentum (C); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2024-03-31 | C (2.3) | F (0.1) | F (0.6) | C (2.3) | D+ (1.5) | D (1.4) |
| 2023-12-31 | C+ (2.6) | C+ (2.5) | D (1.3) | C (2.3) | D (1.5) | C- (2.0) |
| 2023-09-30 | C+ (2.6) | C+ (2.5) | D (1.4) | C (2.3) | D (1.5) | C- (2.1) |
| 2023-06-30 | C+ (2.6) | C+ (2.5) | D+ (1.8) | C (2.3) | D (1.5) | C- (2.1) |